Highlights 

  • Crinetics launches the pivotal Phase 3 CAREFNDR trial testing once daily paltusotine in adults with carcinoid syndrome. 
  • Study aims to enroll 141 participants across multiple centers with flushing reduction as the primary endpoint. 
  • Open-label extension will assess long-term safety, efficacy, and tumor control over 104 weeks. 
  • Paltusotine, marketed as PALSONIFY, is already FDA-approved for acromegaly. 
  • Crinetics ended Q3 2025 with USD 1.1 billion in cash, funding operations into 2029. 

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) has initiated its Phase 3 CAREFNDR clinical trial evaluating paltusotine in adults with carcinoid syndrome, marking a major step toward expanding the therapeutic reach of its flagship drug. Carcinoid syndrome affects roughly 20 percent of people with neuroendocrine tumors, most often when malignancies spread to the liver. Its hallmark symptoms—flushing and diarrhea—can significantly erode patient's quality of life, and existing injectable therapies frequently fall short of full symptom management. 

The CAREFNDR study is structured as a multicenter, randomized, double-blind, placebo-controlled trial. It aims to enroll 141 adults who will receive either paltusotine 80 mg once daily or placebo over a 16-week double-blind treatment window. The primary endpoint measures change in daily flushing episodes at week 12, while bowel movement frequency constitutes a key secondary outcome. Upon completing the controlled portion, all eligible participants will enter a 104-week open-label extension to evaluate durability of benefit, safety signals, and potential effects on tumor progression. 

Early Data Demonstrated Meaningful Symptom Relief 

Paltusotine, an oral selective somatostatin receptor type 2 (SST2) agonist, has previously shown encouraging activity in Phase 2 studies for carcinoid syndrome, with rapid and sustained reductions in flushing and bowel movement frequency. Its once-daily oral formulation offers an alternative to monthly injections, a factor that may improve treatment experience and adherence for patients. 

The drug is already marketed in the United States as PALSONIFY for adults with acromegaly who either did not respond sufficiently to surgery or cannot undergo surgical treatment. The U.S. FDA granted approval in September 2025, positioning Crinetics to grow a franchise around its SST2-targeted therapies. 

The Phase 3 launch represents Crinetics’ strategy to broaden PALSONIFY’s clinical utility by validating its benefit across endocrine-related conditions characterized by excess hormone secretion. 

Pipeline Milestones Strengthen Long-Term Outlook 

Beyond paltusotine, Crinetics is advancing several programs across endocrine and oncology indications. The company is progressing CRN09682, an early-stage anti-tumor candidate aimed at SST2-expressing neuroendocrine and other solid tumors. 

Enrollment is expected to begin later this quarter for the CALM-CAH Phase 3 study and the BALANCE-CAH Phase 2/3 pediatric trial evaluating Atumelnant for congenital adrenal hyperplasia. New glucocorticoid reduction data from Cohort 4 of the Phase 2 trial, along with results from a 13-week open-label extension, are anticipated in early 2026. Planning is also underway for a Phase 2/3 program assessing Atumelnant in ACTH-dependent Cushing’s syndrome, with initiation projected for the first half of 2026. 

Financially, Crinetics ended Q3 2025 with USD 1.1 billion in cash, providing runway to carry its development programs through 2029. 

Conclusion 

The initiation of the CAREFNDR Phase 3 trial marks a notable step for Crinetics as it works to extend paltusotine’s clinical applications into carcinoid syndrome. With strong Phase 2 signals, a sizeable long-term extension, and a deep pipeline advancing in parallel, the company is positioning PALSONIFY and its endocrine portfolio for expanded impact in hormone-driven disorders. Upcoming readouts and new trial launches through 2026 are expected to shape Crinetics’ next phase of growth. 

Also read - SynCardia Systems (NASDAQ:PMI) Reaches Milestone with First Implantations of Emperor Artificial Heart